Revolution Medicines revenue and financials
$199.87Change from previous close: −3.76%Absolute change: −$7.81
Fiscal year ending in December. Sources and method on the page Methodology and sources.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -387 | -354 | -274 | -207 | -222 | -194 | -138 | -130 | -128 | -161 | -121 | -100 |
| Depreciation and amortization | 4.5 | 4.5 | 4.6 | 4.0 | 3.6 | 3.4 | 3.1 | 2.6 | 2.6 | 2.5 | 2.6 | 1.8 |
| Capital expenditure | -2.3 | -1.5 | -1.9 | -3.3 | -7.5 | -3.3 | -1.2 | -3.5 | -2.4 | -3.2 | -2.3 | -2.5 |
| Investing cash flow | -1,659 | 173 | 74.9 | 24.8 | 34.3 | -15.9 | -393 | -21.5 | 108 | -248 | -380 | 77.4 |
| Financing cash flow | 2,420 | 239 | 366 | -1.6 | 257 | 0.9 | 874 | 77.3 | 7.5 | 0.8 | 839 | 1.0 |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | -4.0 | — |
| Debt issued | 487 | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | 374 | 57.2 | 166 | -184 | 69.1 | -210 | 343 | -74.6 | -12.7 | -408 | 338 | -22.1 |
| Free cash flow | -390 | -356 | -276 | -211 | -229 | -198 | -140 | -134 | -131 | -164 | -123 | -103 |
| Levered free cash flow | -228 | -207 | -156 | -121 | -122 | -124 | -70.7 | -79.9 | -74.6 | -122 | -29.1 | -55.0 |